Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Article Authors: D Devineni, L Morrow, M Hompesch, D Skee, A Vandebosch, J Murphy, K Ways, S Schwartz

Abstract

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM).

View Now
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. thumbnail